EB 2009 The DEBRA International Epidermolysis Bullosa Research Conference Vienna, 6-8 September 2009
|
|
- Augustus Ball
- 5 years ago
- Views:
Transcription
1 EB 2009 The DEBRA International Epidermolysis Bullosa Research Conference Vienna, 6-8 September 2009 Pohla-Gubo G, Riedl R, Nuess D, Bauer JW, Hintner H The DEBRA International Epidermolysis Bullosa Research Conference (EB 2009) was held in Vienna in September 2009 and was organized by the Epidermolysis Bullosa (EB) patient support organizations DEBRA Austria and DEBRA International. Attendance was by invitation only and limited to senior EB researchers and clinicians. About 70 specialists from 14 nations were discussing the latest achievements in care and research of EB. In parallel with the conference, two of DEBRA s Task Forces held closed satellite workshops: one on research into the aggressive squamous cell carcinomas associated with recessive dystrophic EB (RDEB), and the other reviewing the use of animal models in basic and clinical EB research. EB is a group of mostly inherited, rare (orphan) diseases and affects approximately 500 individuals in Austria, about 30,000 in the European Union and around 500,000 worldwide. EB means, as the name implies, the blistering ( bullous ) breakdown ( lysis ) of the outer skin layer ( epidermis ), which detaches from the deeper dermis layer, forming blisters. EB is caused by mistakes (mutations) in any one of several known genes which code for structural proteins that hold these two skin layers together these mistakes result in the encoded proteins being faulty or completely absent. EB comprises a genetically, as well as clinically, heterogeneous group of skin disorders. EB varies widely in severity and disease characteristics, depending on the location of the mutation and impact the mutation has on the protein s ability to function adequately in the skin. Currently, about 30 clinical subtypes are known. Two decades ago, EB entered the molecular era with the identification of mutations in specific genes expressed within the cutaneous basement membrane zone. So far, mutations in 14 genes have been identified and these form the basis for the development of novel molecular therapies for EB. The aim of the conference was to give an update of current achievements, and:
2 to review progress and barriers in fundamental EB research and the development of clinical solutions to consider research aspects of EB not addressed to date to identify unexplored opportunities and relevant research from complementary areas to reach research- and clinical-community consensus on scientific and development priorities A scientific report of the major topics of the conference has been published recently [1] and here we give a short summary of the main progress in the field of EB research towards improving medical care and raising hope of alleviating and/or curing this serious and rare disease. Four major sessions of the conference, encompassing up to 6 talks each, addressed various aspects of EB: Modifying Gene Expression (1), Cell and Protein Therapies in EB (2), Cancer (3), and Clinical Trials and Beyond (4). 1. Modifying Gene Expression This session focused on gene therapy. Proof-of-principle for a grafting approach using an ex-vivo gene therapy for one type of EB has already been demonstrated and published in 2006 [2]. The objective was to correct the consequences of a genetic mutation in a patient with junctional EB (JEB). In brief, this was performed by introducing wild-type complementary DNA into the patient s own skin-derived stem cells, which were then grown to produce epithelial sheets for transplantation. Keratinocytes from a JEB patient (mutation in the laminin 332 gene = LAMB3) were cultured and transduced in cell culture. Corrected cell populations with stem-cell characteristics were grown to form epithelial sheets that were then transplanted to the patient's prepared skin. Four years after this procedure, the grafted areas of skin are still expressing sufficient functional laminin. This proof-ofprinciple for a successful gene therapy is encouraging the development of similar technologies with other genes, to treat other types of EB. In a co-operation between the EB House Austria in Salzburg, and Italy (Universities of Modena and Bolzano), within the EU Project Interreg IV, this technology will be applied to another subtype of JEB (mutation in the COL17A1 gene) as well as adapted for use with the collagen 7 gene (COL 7A1) to treat dystrophic EB (DEB). Other laboratories in France and in the United States are pursuing similar gene therapy technology to attempt to treat RDEB.
3 2. Cell and Protein Therapies in EB Local and systemic cell-based therapies The intradermal injection of fibroblasts (skin cells from the dermis) from donors without EB, close to the edges of an area of blistering, has been tested in a limited number of RDEB patients [3] and resulted in local recovery of the skin. Reduced blistering and improved wound healing were observed for several months, even though the allogeneic fibroblasts only survived in the patients skin for a few weeks. Although some patients reported the injections to be painful, particularly near wounds and in areas of scarring, the therapy has not to date caused any side effects. The phase II clinical trial of this fibroblast therapy is currently planned for late Cell-based therapies for RDEB have been extended more recently to the use of stem cells. The early-stage trial of one type of stem-cell therapy, a bone-marrow transplant, has been based on successful preclinical research in a type 7 collagen knock-out mouse model which was used as a target for bone marrow-derived cell transfer [4, 5]. The first bone marrow cell transfer trial on patients with RDEB was initiated in 2007 and the results were published in August 2010 [6]. Seven children between the ages of 15 months and 14 years have been treated to date. One child died before receiving the transplantation, probably as a result of the essential pre-transplantation medical treatment, and another child died some six months after receiving the transplantation, because of transplant rejection and infection. In the six patients who received transplants, all showed some improvement in wound healing and reduced blister formation, at least for a period of time after transplantation. This trial shows that, while bone-marrow transplant is a severe medical procedure, not to be undertaken without serious consideration of the possible consequences, it can, in principle, provide some apparent benefits to some patients with severe RDEB. However, a great deal of further work is needed to refine the procedure, and to study what the long-term effects both benefits and unwanted side-effects are for the people treated to date. A further clinical trial, at the University of Columbia in New York, with a reduced intensity of the chemotherapy, which must precede transplant of the donor bone marrow, has already been initiated [7]. This new gentle approach is expected to have lower morbidity, and mortality, as it may reduce the susceptibility to infection.
4 Bone marrow transplantation to treat EB is at an early stage of development and the identity of the specific cells leading to repair of the structural integrity of the fragile EB skin is still unknown, although further research on this is underway. Protein Replacement Therapy In protein therapy, the aim is to introduce directly into the skin, by intradermal injection, the correctly structured protein, which is completely missing or mutated in EB. The therapeutic protein is produced in large quantities in the laboratory as a recombinant human protein, and then purified. Inserting the correct protein occurs by topical application or local injection. Experiments with intradermal injections of human type 7 collagen into collagen 7-deficient knockout mice showed a reduced level of blistering and extended the survival of these mice [8]. The length of time for which the injected protein persists in the skin depends on the type of the protein and the turnover of this protein in the skin. The half-life of the type 7 collagen molecules in human skin has not yet been determined, but recent studies in mice have suggested that type 7 collagen has a long half-life [9]. This observation, together with the fact that dermatologists are familiar with intracutaneous injections makes the approach very promising at least for some EB subtypes. Unfortunately, attempts to date to apply the same approach to treat JEB with laminin protein failed because it proved too technically difficult to produce the laminin in the laboratory. Compared with gene therapy, the protein replacement is an attractive and apparently safe method because no viruses or living cells are involved in its delivery. Based on these and other observations, clinical trials for phase I and II studies will be initiated. 3. Cancer Squamous cell carcinoma (SCC) occurs specifically in patients with RDEB, most commonly in their third or fourth decade and primarily on the extremities (hands and feet) [10]. Multiple tumours arise independently, and at the same time. They have a high tendency towards metastatic spread and only surgical removal is an effective therapeutic option. In chronic wounds, a major diagnostic challenge is to identify areas where cancers are initiating or may be already malignant. Three years ago, a DEBRA Task Force was established to develop new diagnostic and therapeutic approaches to skin cancer in EB. Systematic investigation of the mechanisms and molecular events leading to the clinically aggressive behaviour of SCC in EB are currently underway. Among contributing factors,
5 it seems likely that the continuous tissue repair associated with chronic inflammatory processes in persistent wounds is responsible for the severe outcome of SCC in EB skin. 4. Clinical Trials and Beyond Pilot studies and clinical trials have been initiated, especially for the more severe subtypes of EB such as JEB or RDEB (Table 1). Various technologies, mostly in the advanced stages of preclinical research or already in early-stage clinical trials, have been reported [11, 12]. Development of potential therapies must assess the risk/benefit ratios for particular patient groups, and consider likely technical and regulatory challenges in establishing their efficacy and safety. Conclusion The identification of mutations in known EB genes provides the starting point for the development of novel, particularly molecular therapies, for EB. The aim of the conference EB 2009 was to give an update of the current achievements and it was highly successful in assessing the present state of EB research [1]. A range of technologies is now available that may be appropriate for different types of EB. In addition to gene therapy, which was predominant at the time of the previous DEBRA conference in 2006, cell-, small-molecule- (sirna), and protein-treatment approaches have developed rapidly in the past five years. Each technology has its benefits and risks and, it is unlikely that any single therapeutic approach is going to be suitable for all patients, or even all patients with a particular type of EB. However, early types of treatments are now emerging which, as they are refined, should help people with EB, either as a single therapy or, in many cases, in the form of a combination of therapies. For a rare disease like EB, it is obvious that only a close collaboration among experts can speed up translational research. At EB 2009, clinicians and researchers established new international networks for future collaborations to facilitate the challenging treatment of EB patients and to raise hope of alleviating and/or curing this serious rare disease.
6 Table 1 * : Examples of molecular therapies under development for different forms of EB Target disease Nature of therapy Approach Research Stage/Clinical Trial JEB Gene therapy Grafting ex vivo genetically modified Pilot study [2] RDEB Gene therapy Grafting ex-vivo genetically modified Planned for clinical trial 2010 EBS/DDEB Gene therapy Silencing of the dominant mutant allele by sirna Preclinical development RDEB Cell therapy localized Localized injection of allogeneic fibroblasts into the skin Pilot study [3] Phase II 2011 RDEB Cell therapy localized Application of chimeric skin equivalents (fibroblasts Phase IIb ongoing from healthy donors and patient keratinocytes) RDEB Cell therapy systemic Allogeneic bone marrow transplantation (standard Phase I/II [6] procedures) RDEB Cell therapy systemic Allogeneic bone marrow transplantation (reduced Phase I/II [7] intensity conditioning) JEB Cell/Gene Therapy Grafting of autologous keratinocytes from patients with Pilot study [13] revertant mosaicism RDEB Protein Therapy localized Protein replacement by intradermal injection (type 7 collagen) Phase I [8] * Table adapted from Uitto et al, 2010 [1] Abbreviations: DDEB, dominant dystrophic epidermolysis bullosa; EBS, epidermolysis bullosa simplex; JEB, junctional epidermolysis bullosa; RDEB, recessive dystrophic epidermolysis bullosa; sirna, small interfering RNA References [1] Uitto J, McGrath JA, Rodeck U, Bruckner-Tuderman L, Robinson EC (2010): Progress in Epidermolysis Bullosa Research: Toward Treatment and Cure. J Invest Dermatol, 130: [2] Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, Maruggi G, Ferrari G, Provasi E, Bonini C, Capurro S, Conti A, Magnoni C, Giannetti A, De Luca M (2006): Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nature Medicine 12: [3] Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G, Jeffery R, Leigh IM, Navsaria H, McGrath JA (2008): Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128:
7 [4] Chino T, Tamai K, Yamazaki T, Otsuru S, Kikuchi Y, Nimura K, Endo M, Nagai M, Uitto J, Kitajima Y, Kaneda Y (2008): Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 173: [5] Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, Lund T, Slattery C, Uitto J, Christiano AM, Wagner JE, Blazar BR (2009): Correction of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113: [6] Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M,. Keene DR, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, and Tolar J (2010): Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa. N Engl J Med 363: [7] Christiano AM, McGrath JA, Hillman E et al. (2009): Reduced intensity conditioning and allogeneic stem cell transplantation in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 129:(suppl. 1) S56 [8] Remington J, Wang X, Hou Y, Zhou H, Burnett J, Muirhead T, Uitto J, Keene DR, Woodley DT, Chen M (2009): Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17:26-33 [9] Kern JS, Loeckermann S, Fritsch A, Hausser I, Roth W, Magin TM, Mack C, Müller ML, Paul O, Ruther P, Bruckner-Tuderman L (2009): Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther. 17(9): [10] Fine JD, Mellerio JE (2009): Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol 61: [11] Tamai K, Kaneda Y, Uitto J (2009): Molecular therapies for heritable blistering diseases. Trends Mol Med 15:
8 [12] Uitto J (2009): Progress in heritable skin diseases: translational implications of mutation analysis and prospects of molecular therapies. Acta Dermatol Venereol 89: [13] Gostynski A, Deviaene FC, Pasmooij AM, Pas HH, Jonkman MF (2009): Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br J Dermatol 161: Correspondence: Gabriela Pohla-Gubo, PhD Department of Dermatology, EB House Austria Paracelsus Medical University Salzburg Muellner Hauptstrasse Salzburg AUSTRIA mailto:g.pohla-gubo@salk.at
Citation for published version (APA): Gostynski, A. (2014). Revertant cell therapy for epidermolysis bullosa [S.l.]: [S.n.]
University of Groningen Revertant cell therapy for epidermolysis bullosa Gostynski, Antoni IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationEUROPEAN REFERENCE NETWORKS and PERSPECTIVES for the FUTURE. H.Hintner Department of Dermatology Paracelsus Medical University Salzburg
EUROPEAN REFERENCE NETWORKS and PERSPECTIVES for the FUTURE H.Hintner Department of Dermatology Paracelsus Medical University Salzburg RARE = ORPHAN DISEASES Incidence 1 in 2000 Often life threatening
More informationDEBRA Members Weekend 2017
DEBRA Members Weekend 2017 EB therapy research in Dundee: an update Knocking out the faulty gene & Skipping the faulty exon Peter van den Akker Premium sponsors: EB therapy research in Dundee: an update
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adhesion and migration, the diverse functions of the laminin a3 subunit, 79 87 Alopecia in epidermolysis bullosa, 165 169 Amblyopia and inherited
More informationProgress in Heritable Skin Diseases: Translational Implications of Mutation Analysis and Prospects of Molecular Therapies*
Acta Derm Venereol 2009; 89: 228 235 REVIEW ARTICLE Progress in Heritable Skin Diseases: Translational Implications of Mutation Analysis and Prospects of Molecular Therapies* Jouni Uitto Department of
More informationMild Dystrophic Epidermolysis Bullosa. J. Denyer EB CNS DebRA UK 2009
Mild Dystrophic Epidermolysis Bullosa J. Denyer EB CNS DebRA UK 2009 What is Epidermolysis Bullosa (EB)? EB is a group of inherited disorders in which the skin blisters extremely easily. There are 3 main
More informationEmil D. Kakkis, M.D., Ph.D. President Kakkis EveryLife Foundation
Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the EveryLife Foundation for Rare Diseases for educational purposes only. They are for use by drug development professionals
More informationA REPORT OF TWO CASES OF SQUAMOUS CELL CARCINOMA OF THE HAND IN PATIENTS WITH EPIDERMOLYSIS BULLOSA DYSTROPHICA
Basrah Journal Case Report Of Surgery A REPORT OF TWO CASES OF SQUAMOUS CELL CARCINOMA OF THE HAND IN PATIENTS WITH EPIDERMOLYSIS BULLOSA DYSTROPHICA MB,ChB, Assist. Prof., FICMS, Consultant Orthopaedic
More informationDYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB)
DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) 1. Introduction Dystrophic epidermolysis bullosa is an umbrella term for all forms of EB, where the blisters are formed in the dermis layer of the skin. "Dystrophic"
More informationCONFLICT OF INTEREST DISCLOSURE
WHEN CHILDHOOD HURTS: EPIDERMOLYSIS BULLOSA JENNY STYERS, RN-BC, MSN, CPNP-AC/PC LYNN CLARK, RN, MS, CPNP-PC, AP-PMN CONFLICT OF INTEREST DISCLOSURE JENNY STYERS, RN-BC, MSN, CPNP-AC/PC NOTHING TO DISCLOSE
More informationDr Saleem Taibjee. Consultant Dermatologist & Dermatopathologist
Dr Saleem Taibjee saleem.taibjee@dchft.nhs.uk Consultant Dermatologist & Dermatopathologist Case S14-10797 and S15-4023 F50. Previous blistering, now marked milia on dorsum of hands. 4mm punch biopsy The
More informationScholars Journal of Medical Case Reports
Scholars Journal of Medical Case Reports Sch J Med Case Rep 2015; 3(9B):896-900 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources)
More informationA global network for EB specialists
Clinical Network of EB Centres and Experts A global network for EB specialists DEBRA International Annual Congress Paris, France September 19-21, 2014 Gabriela Pohla-Gubo, PhD Department of Dermatology
More informationSWISS SOCIETY OF NEONATOLOGY. Neonatal blistering - a butterfly child
SWISS SOCIETY OF NEONATOLOGY Neonatal blistering - a butterfly child August 2010 2 Kaelin S, Weibel L, Arlettaz Mieth R, Neonatal Intensive Care Unit (KS, AMR), Department of Dermatology (WL), University
More informationBone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa
original article Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa John E. Wagner, M.D., Akemi Ishida-Yamamoto, M.D., Ph.D., John A. McGrath, M.D., Maria Hordinsky, M.D., Douglas
More informationInteresting Case Series. A rapid response to matrix therapy with RGTA in severe epidermolysis bullosa
Interesting Case Series A rapid response to matrix therapy with RGTA in severe epidermolysis bullosa Al Malaq, Ali*; Barritault Denis** * King Faisal Specialist Hospital and Research Center, Riyadh KSA,
More informationNovel and recurrent COL7A1 mutations in Chinese patients with dystrophic epidermolysis bullosa pruriginosa
Case Report Novel and recurrent COL7A1 mutations in Chinese patients with dystrophic epidermolysis bullosa pruriginosa K.J. Zhu*, C.Y. Zhu*, Y. Zhou and Y.M. Fan Department of Dermatology, Affiliated Hospital
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Severe generalized recessive dystrophic epidermolysis bullosa (Hallopeau-Siemen s) : a case report Iffat Hassan, Mohammad Abid Keen Journal of Pediatric Sciences 2013;5:e190
More informationIdentical Glycine Substitution Mutations in Type VII Collagen May Underlie Both Dominant and Recessive Forms of Dystrophic Epidermolysis Bullosa
Acta Derm Venereol 2011: 91: 262 266 INVESTIGATIVE REPORT Identical Glycine Substitution Mutations in Type VII Collagen May Underlie Both Dominant and Recessive Forms of Dystrophic Epidermolysis Bullosa
More informationEnteral Nutrition in Children with Recessive Dystrophic Epidermolysis Bullosa
Enteral Nutrition in Children with Recessive Dystrophic Epidermolysis Bullosa Virginie Colomb, MD, PhD Christine Bodemer, MD, PhD Necker Enfants Malades Hospital, Paris DebRA conference Avignon, November
More informationMolecular Basis of Epidermolysis Bullosa
REVIEW ARTICLES Molecular Basis of Epidermolysis Bullosa Dr. K. Y. Chow Social Hygiene Service (Dermatology), Department of Health, Hong Kong ABSTRACT The dermal-epidermal anchoring complex is of critical
More informationEPIDERMOLYSIS BULLOSA
EPIDERMOLYSIS BULLOSA Definition Epidermolysis bullosa (EB) is a term used to describe a group of rare mainly hereditary, chronic, non-inflammatory diseases of skin and mucous membranes. EB is characterized
More informationFrom Marrow to Matrix: Novel Gene and Cell Therapies for Epidermolysis Bullosa
The American Society of Gene & Cell Therapy review From Marrow to Matrix: Novel Gene and Cell Therapies for Epidermolysis Bullosa Beau R Webber 1 and Jakub Tolar 1,2 1 Department of Pediatrics, Division
More informationErythema gyratumrepens-like eruption in a patient with epidermolysisbullosaacquisita associated with ulcerative colitis
Erythema gyratumrepens-like eruption in a patient with epidermolysisbullosaacquisita associated with ulcerative colitis A. España C. Sitaru* M. Pretel L. Aguado J. Jimenez# Department of Dermatology, University
More informationEpidermolysis bullosa in the medical practice of a general practitioner: a study of two cases
Pediatr Pol 2019; 94 (1): 58 62 DOI: https://doi.org/10.5114/polp.2019.83746 Submitted: 11.11.2018; Accepted: 9.02.2019; Published: 27.02.2019 Case report Epidermolysis bullosa in the medical practice
More informationRecent Advances in the Molecular Pathology of Bullous Skin Disorders
1 Bahrain Medical Bulletin, Vol. 27, No. 2, June 2005 Recent Advances in the Molecular Pathology of Bullous Skin Disorders John A McGrath* Maintenance of an intact epidermis depends on secure adhesion
More informationGentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients
The Journal of Clinical Investigation Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients David T. Woodley, 1 Jon Cogan, 1 Yingping Hou, 1 Chao Lyu, 1
More informationGentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients
Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients David T. Woodley,, Douglas Keene, Mei Chen J Clin Invest. 2017;127(8):3028-3038. https://doi.org/10.1172/jci92707.
More informationPreliminary evaluation of cord blood platelet gel for the treatment of skin lesions in children with dystrophic epidermolysis bullosa
Case Report Preliminary evaluation of cord blood platelet gel for the treatment of skin lesions in children dystrophic epidermolysis bullosa Gianluca Tadini 1,2, Sophie Guez 2, Lidia Pezzani 2, Maurizio
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationSection D: The Molecular Biology of Cancer
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
More informationUniversity of Groningen. The Pain Quality Assessment Scale for epidermolysis bullosa Schrader, Nicholas; Yuen, Wing Y; Jonkman, Marcel F.
University of Groningen The Pain Quality Assessment Scale for epidermolysis bullosa Schrader, Nicholas; Yuen, Wing Y; Jonkman, Marcel F. Published in: Acta dermato-venereologica DOI: 10.2340/00015555-2827
More informationCalcium alginate/bone marrow mesenchymal stem cells combined with degradation membrane for repair of skin defects
19 32 2015 08 06 Chinese Journal of Tissue Engineering Research August 6, 2015 Vol.19, No.32 1 2 2 3 4 2 5 ( 1 116044 2 5 110034 3 110024 4 110000) 1 2 3 C 2 15 3 ( ) ( 1 ) ( 2 ) 7 14 21 d 14 21 d 21 d
More informationEpicel (cultured epidermal autografts) HDE# BH Patient Information
Epicel (cultured epidermal autografts) HDE# BH990200 Patient Information This leaflet is designed to help you understand Epicel (cultured epidermal autografts) and its use for the treatment of burn wound.
More informationEye Care for EB Patients Strategies to prevent blistering, scarring and vision loss
Eye Care for EB Patients Strategies to prevent blistering, scarring and vision loss DEBRA Care Conference 7.23.18 Vicki M. Chen, MD Assistant Professor of Ophthalmology New England Eye Center Tufts Medical
More informationA rare case of skin blistering and esophageal stenosis in the course of epidermolysis bullosa - case report and literature review
Michalak et al. BMC Gastroenterology (2018) 18:47 https://doi.org/10.1186/s12876-018-0771-5 CASE REPORT Open Access A rare case of skin blistering and esophageal stenosis in the course of epidermolysis
More informationSarolta Kárpáti. Technology Transfer in Diagnostic Pathology, 5th Central European Regional Meeting May 1, 2010, Siófok
Blistering diseases Sarolta Kárpáti SEMMELWEIS UNIVERSITY, BUDAPEST Technology Transfer in Diagnostic Pathology, 5th Central European Regional Meeting May 1, 2010, Siófok Blistering diseases Autoimmune
More informationInjection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue
Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue Susana Ortiz-Urda, 1 Qun Lin, 1 Cheryl L. Green, 1 Douglas R. Keene, 2 M. Peter Marinkovich,
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationType IV collagen and laminin staining patterns in benign
J Clin Pathol 1989;42:1173-1177 Type IV collagen and laminin staining patterns in benign and malignant cutaneous lesions RONA M MacKIE, D B CLELLAND, CHRISTINE J SKERROW From the Department ofdermatology,
More informationSQUAMOUS CELL CARCINOMA
SQUAMOUS CELL CARCINOMA What are the aims of this leaflet? This leaflet has been written to help you understand more about squamous cell carcinomas of the skin. It tells you what they are, what causes
More information- Conclusion: This study confirmed the very good acceptability and efficacy of Urgotul in the treatment of skin lesions in patients with EB.
www.journalofwoundcare.com Using Urgotul dressing for the management of epidermolysis bullosa skin lesions VOL 14, NO 10, November 2005 Objective: To evaluate the acceptability, tolerance and efficacy
More informationPACIFIC JOURNAL OF MEDICAL SCIENCES ISSN:
PACIFIC JOURNAL OF MEDICAL SCIENCES {Formerly: Medical Sciences Bulletin} ISSN: 2072 1625 Pac. J. Med. Sci. (PJMS) www.pacjmedsci.com. Email: pacjmedsci@gmail.com. UNUSUAL OCCURRENCE OF EPIDERMOLYSIS BULLOSA
More informationLife with Epidermolysis Bullosa Perception and experience of people living with EB and their caregivers
Life with Epidermolysis Bullosa Perception and experience of people living with EB and their caregivers Brief presentation of Results Cinzia Pilo Debra International Congress Zagreb, 23 rd September 2016
More informationSWISS SOCIETY OF NEONATOLOGY. Life and death of a butterfly child born in a resourcelimited
SWISS SOCIETY OF NEONATOLOGY Life and death of a butterfly child born in a resourcelimited country January 2017 Alfonso Deliz O, Berger TM, Gubler D, Rundu State Hospital (ADO, BTM), Rundu, Namibia, The
More informationCancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz
Cancer and Oncogenes Bioscience in the 21 st Century Linda Lowe-Krentz December 1, 2010 Just a Few Numbers Becoming Cancer Genetic Defects Drugs Our friends and family 25 More mutations as 20 you get older
More informationComment on Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis
Accepted Manuscript Comment on Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis Maglie Roberto, MD, Antiga Emiliano, MD, PhD, Caproni Marzia, MD, PhD PII: S0190-9622(17)32812-8
More informationREPORT OF EXPERIENCES:
REPORT OF EXPERIENCES: Non Adherent Dressings in Fragile Skin Conditions: The Use of Soft Silicone Coated Polyurethane Foam Dressing (Mepilex ) in Hereditary and Acquired Bullous Skin Diseases. Hauke Schumann
More informationالسكري للداء مرافقة فقاعات diabeticorum= Bullosis
1 / 6 Bullosis diabeticorum Bullous disease of diabetes (bullosis diabeticorum) is a distinct, spontaneous, noninflammatory, blistering condition of acral skin unique to patients with diabetes mellitus.
More informationThe differential diagnosis of dysphagia with onset in CASE REPORT
GASTROENTEROLOGY 2002;122:220 225 CASE REPORT Esophageal Stenosis in Childhood: Dystrophic Epidermolysis Bullosa Without Skin Blistering Due to Collagen VII Mutations KLAUS PETER ZIMMER,* HAUKE SCHUMANN,
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationInternational Symposium on the Ehlers-Danlos Syndromes
It is with great pleasure that we invite you to participate in the International Symposium on the Ehlers-Danlos Syndromes September 26 29, 2018 The conference will take place in beautiful Ghent, Belgium,
More informationMOHS MICROGRAPHIC SURGERY
MOHS MICROGRAPHIC SURGERY What are the aims of this leaflet? This leaflet has been written to help you understand more about Mohs micrographic surgery. It tells you what it is, what is involved and what
More informationROLE OF INFLAMMATION IN EB: Implication for new therapeutic approaches
DEBRA INTERNATIONAL CONGRESS Zagreb, 22-25 September 2016 ROLE OF INFLAMMATION IN EB: Implication for new therapeutic approaches SUSANNA ESPOSITO Pediatric Highly Intensive Care Unit, Università degli
More informationCancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen.
Cancer Single cells divide by mitosis to form many cells. This cells undergo physical and chemical changes in order to perform specific functions. (we say the cells have Differentiated) in this way we
More informationYUJI YAMAGUCHI Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences
Nagoya Med. J., 149 Current status of regenerative medicine through the treatment for intractable skin wounds YUJI YAMAGUCHI Department of Geriatric and Environmental Dermatology, Nagoya City University
More informationPeriodontal Management of a Patient with Kindler Syndrome
Case Report Received: April.20-2013 Accepted: Jan.13-2014 Periodontal Management of a Patient with Kindler Syndrome Torkzaban, P.* Moradihaghgoo, J.**, Shams, B.*** Gholami, L.**** Sabzeghabaie, M.*****
More information4 Skin and Body Membranes Study Guide
Name: SKIN AND BODY MEMBRANES: 4 Skin and Body Membranes Study Guide Period: Body membranes, which cover body surfaces, line its cavities, and form protective sheets around organs, fall into two major
More informationAcquired and Inherited Bullous Diseases
Acquired and Inherited Bullous Diseases Erin Wei MD Brigham and Women s Hospital, Department of Dermatology Instructor, Harvard Medical School Director, Bullous Disease Clinic No disclosures Conflict of
More informationWhat is melanoma? Melanoma dealing with the diagnosis. What is melanoma?
Melanoma is a form of cancer which develops from that part of the skin which produces its colour. It grows from the cell which produces the brown pigment in our skin: the melanocyte. Often the melanoma
More informationCurrent concepts of autoimmune bullous diseases Advances in pathogenesis. Luca Borradori
Current concepts of autoimmune bullous diseases Advances in pathogenesis Luca Borradori Dept. of Dermatology Inselspital, University Hospital of Berne Switzerland Luca.Borradori@insel.ch Autoimmune bullous
More informationCastle Creek Pharmaceuticals
Castle Creek Pharmaceuticals Dermatology Summit Entrepreneurial Showcase 2018 Michael Derby, CEO January 7, 2018 Castle Creek Pharma Driving innovation in dermatology We are a high-growth biotech company
More informationSquamous cell carcinomas of the skin responsive to erlotinib: 5 cases
Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases William Read, Emory University Kevin T. Brumund, Moores Cancer Center Robert A. Weisman, Moores Cancer Center Angel Q. Nguyen, Moores
More informationHouse Committee on Appropriations: Subcommittee on Labor, Health and Human Services, Education and Related Agencies Public Witness Testimony
House Committee on Appropriations: Subcommittee on Labor, Health and Human Services, Education and Related Agencies Public Witness Testimony Testimony of Brett Kopelan, Executive Director, debra of America
More informationHHS Public Access Author manuscript J Invest Dermatol. Author manuscript; available in PMC 2015 January 01.
RNA-seq Permits a Closer Look at Normal Skin and Psoriasis Gene Networks David Quigley 1,2,3 1 Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco,
More informationEpidermolysis bullosa Report from observation charts
Orofacial function of persons having Epidermolysis bullosa Report from observation charts The survey comprises 20 observation charts. Estimated occurrence: 50:000 000 inhabitants. Etiology: There are both
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationGuidelines for the Anesthetic Management of Epidermolysis Bullosa (EB) Louise K Furukawa, MD. Elliot Krane, M.D.
Guidelines for the Anesthetic Management of is Bullosa (EB) Louise K Furukawa, MD Elliot Krane, M.D. Guidelines For The Anesthetic Management Of is Bullosa (EB) Table of Contents Table of Contents... 2
More informationCase Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing
Case Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing Andrew C. Krakowski, MD a,b, Pedram Ghasri, MD c Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating
More informationRegeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018
A D E E P E R L O O K When detected early, most cases of local cutaneous squamous cell carcinoma are easily treated and usually cured. But when they become more advanced, this second most common form of
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationUnited Nations General Assembly June 8, 2011
Remarks by Dr. Mathilde Krim United Nations General Assembly June 8, 2011 I am Mathilde Krim, the Founding Chairman of amfar, The Foundation for AIDS Research. This is a not-for-profit foundation based
More informationPrevention. Skin cancer is the most common cancer in the. The Science of. by Laura Brockway-Lunardi, Ph.D.
66 DERMASCOPE June 2012 The Science of Prevention by Laura Brockway-Lunardi, Ph.D. Skin cancer is the most common cancer in the U.S. with more than two million Americans diagnosed annually. Basal cell
More informationExtracutaneous manifestations of Epidermolysis Bullosa
Extracutaneous manifestations of Epidermolysis Bullosa DEBRA International Congress Toronto 13th September 2012 Dr Anna Martinez Great Ormond Street Hospital London 400 EB: more than just skin deep Multisystemic
More informationERN-Skin. With the support of the EADV
With the support of the EADV ERN-Skin Prof. C. Bodemer Head of the Department of Dermatology Hôpital Necker Enfants Malades President of the Genodermatoses & Rare Skin Disorders Network Scien8fic Commi;ee
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationThe number of new cases is expected to rise by about 70% over the next 2 decades.
World Health Organization Cancer Fact sheet February 2017 Key facts Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases in 2012 1. The number
More informationThe Adult hand and EB Rachel Box Clinical Specialist St Thomas Hospital
The Adult hand and EB Rachel Box Clinical Specialist St Thomas Hospital All types of EB affect the Hand. Patients treated often have Junctional, Dystrophic or Recessive Dystrophic EB. Skin, mucosal linings
More informationPrinciples of Anatomy and Physiology
Principles of Anatomy and Physiology 14 th Edition CHAPTER 5 The Integumentary System Introduction The organs of the integumentary system include the skin and its accessory structures including hair, nails,
More information- is a common disease - 1 person in 3 can expect to contract cancer at some stage in their life -1 person in 5 can expect to die from it
MBB157 Dr D Mangnall The Molecular Basis of Disease CANCER Lecture 1 One of the simpler (and better) definitions of cancer comes from the American Cancer Society, who define cancer as; 'Cancer is a group
More informationHAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People Histiocytosis UK Introduction Despite the misery it causes, Histiocytosis is too rare a disease to have generated substantial research in medical
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationThe Integumentary System : Embryology & Genetic Bases. Purnomo Soeharso Department of Medical Biology FMUI
The Integumentary System : Embryology & Genetic Bases Purnomo Soeharso Department of Medical Biology FMUI Tissue organization of the skin (integumentum) : - Epidermis stratified epithelium on the outer
More informationimmunodeficiency (ADA-SCID)
ADA-SCID Adenosine deaminasedeficient severe combined immunodeficiency (ADA-SCID) Additional information for families hello@piduk.org 0800 987 898 www.piduk.org About this leaflet This leaflet has been
More informationCongenital bleeding disorders
Congenital bleeding disorders Overview Factor VIII von Willebrand Factor Complex factor VIII von Willebrand factor (vwf) complex circulate as a complex + factor IX intrinsic pathway Platelets bind via
More informationEpidermolysis Bullosa Acquisita
Introduction Epidermolysis Bullosa Acquisita Pages with reference to book, From 192 To 194 Nasser Rashid Dar ( Departments of Dermatology, Combined Military Hospital, Peshawar. ) Ahsan Hameed, Ashfaq Ahmad
More information5-Part Series on Alport Syndrome by Dr. Clifford Kashtan
5-Part Series on Alport Syndrome by Dr. Clifford Kashtan Dr. Clifford Kashtan is the director of the Alport Syndrome Treatments and Outcomes Registry (ASTOR) and a member of the ASF Medical Advisory Committee.
More informationCase Report. Gurleen Kaur Dhillon, Bikramdeep Singh, Meenakshi Iyer, Shalu Chandna INTRODUCTION
Case Report Periodontitis and Hereditary Epidermolysis Bullosa: A Rare Case Report and Review Gurleen Kaur Dhillon, Bikramdeep Singh, Meenakshi Iyer, Shalu Chandna Department of Periodontology and Oral
More informationParacrine Mechanisms in Adult Stem Cell Signaling and Therapy
Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy Massimiliano Gnecchi, Zhiping Zhang, Aiguo Ni, Victor J. Dzau Circulation Research 2008 Nov 21;103(11):1204-19 Introduction(1) After AMI all
More informationThe treatment of destructive periodontal disease, due to specific periodontopathic
1 1 INTRODUCTION The treatment of destructive periodontal disease, due to specific periodontopathic bacteria, aims at the regeneration of a periodontal attachment composed of new cementum, alveolar bone
More informationEarly cell death (FGF) B No RunX transcription factor produced Yes No differentiation
Solution Key - Practice Questions Question 1 a) A recent publication has shown that the fat stem cells (FSC) can act as bone stem cells to repair cavities in the skull, when transplanted into immuno-compromised
More informationProblem Set 8 Key 1 of 8
7.06 2003 Problem Set 8 Key 1 of 8 7.06 2003 Problem Set 8 Key 1. As a bright MD/PhD, you are interested in questions about the control of cell number in the body. Recently, you've seen three patients
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationSleeping Beauty: Current applications and future strategies. CAR-TCR Summit 2017 Partow Kebriaei, MD
Sleeping Beauty: Current applications and future strategies CAR-TCR Summit 2017 Partow Kebriaei, MD Outline Chimeric antigen receptor (CAR) technology Viral versus nonviral vectors Results of current clinical
More informationStem Cells. Induced Stem Cells
Induced Stem Cells Stem Cells Mouse and human somatic cells can either be reprogrammed to a pluripotent state or converted to another lineage with a combination of transcription factors suggesting that
More informationAnalysis of single gene effects 1. Quantitative analysis of single gene effects. Gregory Carey, Barbara J. Bowers, Jeanne M.
Analysis of single gene effects 1 Quantitative analysis of single gene effects Gregory Carey, Barbara J. Bowers, Jeanne M. Wehner From the Department of Psychology (GC, JMW) and Institute for Behavioral
More informationProgram First World Conference on Ichthyosis August 31 September 2, 2007 Münster, Germany
Date: August 10, 2007 Program First World Conference on Ichthyosis August 31 September 2, 2007 Münster, Germany Organized by Network for Ichthyoses and related keratinization disorders (NIRK) together
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More information